Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 2/20 | 0.39 |
| ▸ | RXRB | P28702 | 2/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL477443 | 0.83 | LMNA (0.44) | SMN1; SMN2RIPK1SLC6A4AOC3L3MBTL1 | |
| SCHEMBL28973554 | 0.83 | LMNA (0.44) | SMN1; SMN2RIPK1SLC6A4AOC3L3MBTL1 | |
| SCHEMBL477635 | 0.83 | LMNA (0.44) | SMN1; SMN2RIPK1SLC6A4AOC3L3MBTL1 | |
| SCHEMBL14033674 | 0.80 | IDO1 (0.54) | TACR1 | |
| SCHEMBL26326672 | 0.78 | CA12 (0.50) | — | |
| SCHEMBL23357364 | 0.78 | GABRA1 (0.42) | CYP3A4CYP1A2CYP2C9TSHRCYP2C19 | |
| SCHEMBL9778009 | 0.78 | SMN1; SMN2 (0.54) | TSHRCNR2SMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL9136246 | 0.77 | TSHR (0.50) | CYP3A4CYP1A2CYP2C9TSHRCYP2C19 | |
| SCHEMBL30709713 | 0.77 | TSHR (0.50) | CYP3A4CYP1A2CYP2C9TSHRCYP2C19 | |
| SCHEMBL28647604 | 0.76 | CYP3A4 (0.41) | CYP3A4CYP1A2CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113549062-B | Chiral quaternary ammonium salt phase transfer catalyst with high steric hindrance derived from cinchona alkaloid and synthesis method thereof | 南京工业大学 | 2022-08-09 | — | — | CN | claimed |
| CN-115023460-B | Microporous membrane and method for producing same | 旭化成株式会社 | 2024-04-05 | — | — | CN | disclosed |
| CN-117120528-A | Resin pellet composition, method for producing same, and method for producing microporous membrane | 旭化成株式会社 | 2023-11-24 | — | — | CN | disclosed |
| CN-116710507-A | Resin raw material composition for molding, resin raw material composition for microporous film, and method for producing same | 旭化成株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2023-08-31 | — | — | US | disclosed |
| CN-115023460-A | Microporous membrane and method for producing same | 旭化成株式会社 | 2022-09-06 | — | — | CN | disclosed |
| CN-113549062-B | Chiral quaternary ammonium salt phase transfer catalyst with high steric hindrance derived from cinchona alkaloid and synthesis method thereof | 南京工业大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-113549062-A | Chiral quaternary ammonium salt phase transfer catalyst with high steric hindrance derived from cinchona alkaloid and synthesis method thereof | 南京工业大学 | 2021-10-26 | — | — | CN | disclosed |
| WO-2021153792-A1 | MICROPOROUS FILM, AND METHOD FOR PRODUCING SAME | 旭化成株式会社 | 2021-08-05 | — | — | WO | disclosed |
| CN-105189649-B | Polylactic acid resin composition | SK化学公司 | 2020-08-04 | — | — | CN | disclosed |
| EP-1354023-A2 | LUBRICATING OIL COMPOSITION | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002053687-A2 | LUBRICATING OIL COMPOSITION | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2002-07-11 | — | — | WO | disclosed |
| CN-1144236-A | Flame retardant insulation compositions having enhanced curability | QUANTUM CHEM CORP (US) | 1997-03-05 | — | — | CN | disclosed |
| EP-0149191-A2 | Low modulus structural foam | GENERAL ELECTRIC COMPANY (US) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271988-A1 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | HPD, TALDO1, OGG1 | CYP3A4 117/4885CYP1A2 537/4885CYP2C9 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.